

In Silico Study on the Potential of Guaiacol Extract from Green Tea (*Camellia sinensis*) as a Stimulant for Carbanic Anhydrase II in Renal Tubular Acidosis

Rahadian Zainul^{1,9,*}, Rismi Verawati¹, Agus Suprijono², Riso Sari Mandeli³, Asri Peni Wulandari⁴, Dony Novaliendry⁵, Ritmaleni⁶, Linda Rosalina⁷, Muhammad Arya Ghifari⁸, Amalia Putri Lubis¹, Viol Dhea Kharisma^{10,11}, Vikash Jakhmola¹², Maksim Rebezov^{13,14}, ANM Ansori^{10,12}

¹Department of Chemistry, Faculty of Mathematics and Natural Sciences, Universitas Negeri Padang, INDONESIA.

²Department of Pharmacy, Sekolah Tinggi Ilmu Farmasi Yayasan Farmasi Semarang, INDONESIA.

³Environmental and Policy Researcher, Environmental Science Program Universitas Negeri Padang, INDONESIA.

⁴Department of Biology, Faculty of Mathematics and Natural Sciences, Universitas Padjadjaran, INDONESIA.

⁵Electronic Department, Engineering Faculty, Universitas Negeri Padang, Padang, INDONESIA.

⁶Laboratory of Medicinal Chemistry, Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Universitas Gadjah Mada, North Sekip, Yogyakarta, INDONESIA.

⁷Department of Makeup and Beauty, Faculty of Tourism and Hospitality, Universitas Negeri Padang, INDONESIA.

⁸Informatics Engineering, Faculty of Computer Sciences, Universitas Bravijaya, Malang, INDONESIA.

⁹Center for Advanced Material Processing, Artificial Intelligence, and Biophysic Informatics (CAMPBIOTICS), Universitas Negeri Padang, INDONESIA.

¹⁰Faculty of Science and Technology, Universitas Airlangga, Surabaya, INDONESIA.

¹¹Generasi Biologi Indonesia Foundation, Gresik, INDONESIA.

¹²Uttaranchal Institute of Pharmaceutical Sciences, Uttaranchal University, Dehradun, INDIA.

¹³Department of Scientific Research, V. M. Gorbatov Federal Research Center for Food Systems, Moscow, RUSSIAN FEDERATION.

¹⁴Faculty of Biotechnology and Food Engineering, Ural State Agrarian University, Yekaterinburg, RUSSIAN FEDERATION.

Correspondence

Rahadian Zainul

Department of Chemistry, Faculty of Mathematics and Natural Sciences, Universitas Negeri Padang, INDONESIA; Center for Advanced Material Processing, Artificial Intelligence, and Biophysic Informatics (CAMPBIOTICS), Universitas Negeri Padang Indonesia, INDONESIA.

E-mail: rahadianzmsiphd@fmipa.unp.ac.id

History

- Submission Date: 12-05-2023;
- Review completed: 16-06-2023;
- Accepted Date: 24-06-2023.

DOI : 10.5530/pj.2023.15.108

Article Available online

<http://www.phcogj.com/v15/i4>

Copyright

© 2023 Phcogj.Com. This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license.



ABSTRACT

This study explores the potential of Guaiacol, a green tea extract from *Camellia sinensis*, as a stimulant in renal tubular acidosis through *in-silico* investigation on the Carbanic Anhydrase II enzyme. Utilizing comprehensive computational tools including PyMOL, PyRx, Protein Plus, and the Lipinski's Rule of Five, a detailed examination of the molecular structure and its interactions with the target enzyme was conducted. The results from Protein Plus revealed interactions between Guaiacol and Carbanic Anhydrase II. Quantitative parameters were determined with Binding Affinity values of -5, -4.7, and -4.5, along with RMSD values of 0, 0.956, and 1.412. The Lipinski's Rule of Five was employed to evaluate the compound's drug-like properties, with the findings indicating a molecular weight of 124, one hydrogen bond donor, two hydrogen bond acceptors, a log P of 1.4, and a molar reactivity of 34.65. Overall, these findings suggest that Guaiacol holds promising therapeutic potential in the treatment of renal tubular acidosis.

Key words: Molecular Docking, Guaiacol, Carbanic Anhydrase II, Renal Tubular Acidosis, *Camellia sinensis*.

INTRODUCTION

Renal tubular acidosis is a metabolic disorder that occurs when the function of the renal tubules in maintaining acid-base balance is impaired. This condition can cause serious health complications and affect various organ systems. Carbonic Anhydrase II (CA II) is an enzyme involved in the regulation of renal tubular reabsorption of hydrogen and bicarbonate ions.^{1,2} Therefore, research on the development of stimulant agents that can enhance CA II activity is crucial in addressing renal tubular acidosis. Green tea (*Camellia sinensis*) contains active compounds, including Guaiacol, which have been known for their various pharmacological activities. However, to date, there have been no studies specifically investigating the potential of Guaiacol as a stimulant for CA II therapy in renal tubular acidosis.³⁻⁵ Therefore, this *in-silico* study aims to evaluate the potential of Guaiacol as a stimulant for CA II and elucidate the underlying molecular interactions through computational approaches. This research can provide new insights into the development of innovative therapies to address renal tubular acidosis.^{6,7}

To date, research on renal tubular acidosis and the development of effective therapies is still limited. Several previous studies have revealed the crucial role of Carbonic Anhydrase II (CA II) in the regulation of acid-base balance in the renal tubules. However, no study has specifically focused on the potential of Guaiacol, a green tea extract (*Camellia sinensis*), as a CA II stimulant in the treatment of renal tubular acidosis.^{8,9} The *in-silico* approach used in this study provides an advantage in analyzing the

molecular interactions between Guaiacol and CA II in detail. By combining information on molecular interactions and pharmacokinetic parameters, this research is expected to make a significant contribution to the development of new effective and innovative therapies for addressing renal tubular acidosis.¹⁰⁻¹²

This study has several novel aspects and significant contributions. Firstly, it explores the potential of Guaiacol, a green tea extract (*Camellia sinensis*), as a stimulant in renal tubular acidosis, which is an approach that has not been previously explored. This study provides new insights into the use of natural compounds as potential therapies for this metabolic disorder. Additionally, the use of an *in-silico* approach in this study offers advantages in analyzing the molecular interactions between Guaiacol and the enzyme Carbonic Anhydrase II, providing a deep understanding of the potential mechanisms involved. The contribution of this research is to provide a strong foundation for the development of innovative therapies in the treatment of renal tubular acidosis.¹³⁻¹⁵ The aim of this study is to evaluate the potential of Guaiacol as a stimulant for Carbonic Anhydrase II and understand the underlying molecular interactions, with the hope of paving the way for the development of new, more effective, and safe therapies for addressing renal tubular acidosis.

MATERIALS AND METHODS

The research methodology employed in this study was systematically and comprehensively designed to investigate the potential of Guaiacol, a green tea extract (*Camellia sinensis*), as a stimulant in renal tubular acidosis using an *in-silico* approach.

Cite this article: Zainul R, Verawati R, Suprijono A, Mandeli RS, Wulandari AP, Novaliendry D, et al. *In Silico* Study on the Potential of Guaiacol Extract from Green Tea (*Camellia sinensis*) as a Stimulant for Carbanic Anhydrase II in Renal Tubular Acidosis. *Pharmacogn J.* 2023;15(4): 494-499.

Firstly, in the initial step, the molecular structure of Guaiacol was obtained from reliable sources and evaluated using the Pymol software (<https://pymol.org/2/>) to ensure its accuracy. Subsequently, the structure of the Carbonic Anhydrase II (CA II) enzyme was obtained from the Protein Data Bank (PDB) (<https://www.rcsb.org/>). Both structures were then loaded into the PyRx software (<https://pyrx.sourceforge.io/>) to facilitate the analysis of molecular interactions between Guaiacol and CA II. The use of PyRx enabled precise molecular modeling, docking, and visualization of interactions with high accuracy.¹⁶⁻¹⁸

Furthermore, Protein Plus (<https://proteins.plus/>) was used to calculate pharmacokinetic parameters and analyze the results of CA II activity enhancement by Guaiacol. In this analysis, the Binding Affinity was calculated to evaluate the strength of the binding between Guaiacol and CA II, while RMSD was used to estimate the stability of the Guaiacol-CA II complex. Additionally, the Lipinski Rule of Five (<https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/lipinskis-rule-of-five>) was employed to evaluate the physicochemical properties of Guaiacol and ensure that the compound meets the qualifying criteria as a potential drug.¹⁹⁻²²

The entire research process was conducted virtually through an *in-silico* approach, avoiding the need for expensive and time-consuming *in-vivo* experiments. This method provides an efficient and effective approach to analyzing molecular interactions and pharmacokinetic parameters of Guaiacol as a stimulant in renal tubular acidosis.^{23,24}

RESULTS AND DISCUSSION

The analysis of the research results demonstrates the success in exploring the potential of Guaiacol as a stimulant in renal tubular acidosis through an *in-silico* approach. The calculated Binding Affinity values of -5.0, -4.7, and -4.5 indicate that Guaiacol has a strong affinity for Carbonic Anhydrase II (CA II), suggesting the possibility of significant interactions between Guaiacol and the target enzyme. Furthermore, the RMSD analysis shows values of 0.0, 0.956, and 1.412, indicating the stability of the Guaiacol-CA II complex. Please refer to Table 1 for the detailed results of the Binding Affinity and RMSD calculations obtained using the PyRx application.^{25,27}

The analysis of pharmacokinetic parameters using the Lipinski Rule of Five indicates that Guaiacol meets the qualification criteria as a potential drug. Despite its low molecular weight of 124, Guaiacol satisfies the limits for the number of hydrogen bond donors (1) and hydrogen bond acceptors (2). The Log P value of 1.4 indicates adequate solubility, while the molar reactivity of 34.65 suggests potential reactive

Table 1: Binding affinity and RMSD results of Guaiacol docking with Carbonic Anhydrase II.

Ligand	Binding Affinity	rmsd/ ub	rmsd/ lb
Carbonic_anhydrase_II_bersih_guaiacol_minimize	-5	0	0
Carbonic_anhydrase_II_bersih_guaiacol_minimize	-4.7	2.926	1.412
Carbonic_anhydrase_II_bersih_guaiacol_minimize	-4.5	2.266	0.956
Carbonic_anhydrase_II_bersih_guaiacol_minimize	-4.4	3.387	1.56
Carbonic_anhydrase_II_bersih_guaiacol_minimize	-4.4	4.528	3.016
Carbonic_anhydrase_II_bersih_guaiacol_minimize	-4.3	4.749	2.045
Carbonic_anhydrase_II_bersih_guaiacol_minimize	-4.3	2.882	1.998
Carbonic_anhydrase_II_bersih_guaiacol_minimize	-4.1	3.252	1.938
Carbonic_anhydrase_II_bersih_guaiacol_minimize	-4.1	4.246	3.179

Table 2: Lipinski rule of five results for Guaiacol.

Mass	Hydrogen bond donor	Hydrogen bond acceptor	LOGP	Molar reactivity
124.000000	1	2	1.400800	34.658794




Figure 1: Visualization of the interaction between Guaiacol and Carbonic Anhydrase II

activity.²⁸⁻³⁰ Table 2 presents the Lipinski Rule of Five data, and Figure 1 shows the Protein Plus results for Guaiacol and Carbonic Anhydrase II.

Overall, this analysis demonstrates the potential of Guaiacol as a drug for treating renal tubular acidosis through its interaction with CA II. The success of this research in using the *in-silico* approach contributes significantly to the development of new effective and safe therapies. However, it is important to note that these findings are speculative, and further research, including biological and clinical trials, is required to confirm the therapeutic potential of Guaiacol in the treatment of renal tubular acidosis.^{31,32}

This study provides important interpretations regarding the potential of Guaiacol as a stimulant in renal tubular acidosis. The finding that Guaiacol exhibits strong affinity to the Carbonic Anhydrase II (CA II) enzyme through the analysis of Binding Affinity suggests significant molecular interactions between these entities. This indicates that Guaiacol may influence the activity of CA II in regulating the acid-base balance in the renal tubules. This interpretation directly highlights the potential role of Guaiacol as a drug in addressing metabolic disorders associated with renal tubular acidosis.^{33,34}

Furthermore, the analysis of RMSD results depicts the stability level of the Guaiacol-CA II complex. The stability resulting from the interaction between Guaiacol and CA II is a key factor in determining the success of a drug in stimulating enzyme activity. These results indicate that the Guaiacol-CA II complex exhibits adequate stability, which is a positive indicator for the prospects of developing therapy using Guaiacol.^{35,36}

The last interpretation pertains to the analysis of pharmacokinetic parameters using the Lipinski Rule of Five. These results indicate that Guaiacol meets the qualifying criteria as a potential drug. Despite its relatively low molecular weight, Guaiacol satisfies the limitations on the number of hydrogen bond donors and acceptors. Additionally, the recorded log P and molar reactivity values demonstrate physicochemical properties that align with the desired characteristics of a drug. This provides confidence that Guaiacol possesses pharmacological potential worthy of use in the treatment of renal tubular acidosis.³⁷⁻³⁹

In conclusion, the interpretation of this research demonstrates that Guaiacol has the potential as a stimulant in renal tubular acidosis through its interaction with Carbonic Anhydrase II. These findings provide a foundation for the development of innovative therapies to




Figure 2: (a) 2D Visualisasi Ligan guaiacol (b) 3D Visualisasi Ligan guaiacol




Figure 3: (a) Protein carbanic anhydrase II (b) Protein carbanic anhydrase II

address this metabolic disorder.¹⁴ However, it is important to note that these interpretations are based on the *in-silico* approach, and further studies, including biological and clinical trials, are necessary to confirm the effectiveness and safety of using Guaiacol as a drug in the treatment of renal tubular acidosis.³⁹⁻⁴¹

Overall, comparisons with previous research support the findings of this study regarding the potential of Guaiacol as a stimulant in renal tubular acidosis. Similar findings involving other CA II inhibitor compounds and the use of natural compounds to intervene in metabolic pathways indicate that regulating CA II activity can be an effective approach in addressing renal tubular acidosis.

Furthermore, comparisons with studies involving the use of other natural compounds to affect CA II activity or other metabolic pathways provide additional perspectives on the potential use of natural compounds in the treatment of renal tubular acidosis. This suggests that Guaiacol is not the only natural compound that may have positive effects in addressing this metabolic disorder.

Comparisons with studies utilizing the *in-silico* approach also demonstrate the validity and effectiveness of this approach in analyzing molecular interactions and pharmacokinetic parameters. Similar findings regarding the use of *in-silico* approaches to evaluate interactions with target enzymes or identify potential compounds emphasize the value of computational approaches in drug research.⁴²⁻⁴⁴

However, to strengthen the findings of this research and understand its clinical potential, comparisons with clinical studies or animal research are necessary. Such studies will provide a deeper understanding of the effectiveness and safety of using Guaiacol as a stimulant in the treatment of renal tubular acidosis, as well as provide further evidence of its therapeutic potential. Overall, comparisons with previous research provide support and a more comprehensive understanding of

the potential of Guaiacol as a stimulant in renal tubular acidosis. These findings underscore the importance of further research to validate the *in-silico* results and fully comprehend the effects and therapeutic potential of Guaiacol in addressing this metabolic disorder.⁴⁴⁻⁵⁷ Figures 2 and 3 depict the Guaiacol ligand and Carbanic Anhydrase II protein.

CONCLUSION

Based on the findings of this study, it can be concluded that Guaiacol, an extract from green tea (*Camellia sinensis*), has the potential as a stimulant in addressing renal tubular acidosis. *In-silico* analysis revealed that Guaiacol exhibited strong affinity towards Carbonic Anhydrase II (CA II), which plays a crucial role in acid-base regulation in the renal tubules. The study also demonstrated molecular interactions between Guaiacol and CA II, along with adequate stability of the Guaiacol-CA II complex. The calculated pharmacokinetic parameters indicated that Guaiacol meets the qualification criteria as a potential drug. These findings provide a significant foundation for the development of effective therapies to address renal tubular acidosis.

However, it should be noted that this study solely employed an *in-silico* approach and did not involve biological or clinical testing. Therefore, further research is necessary to validate the effectiveness and safety of Guaiacol as a stimulant in the treatment of renal tubular acidosis. Additional studies incorporating *in vivo* experiments and clinical trials will provide a more comprehensive understanding of the therapeutic potential of Guaiacol and strengthen the findings of this research. Consequently, this study paves the way for the development of innovative therapies that have the potential to provide significant benefits in addressing renal tubular acidosis.

ACKNOWLEDGMENT

We would like to express our heartfelt gratitude to Rector of Universitas Negeri Padang for their generous research funding through the Grant for Full Professor/Professor Contract Number 1484/UN35.15/LT/2023.


REFERENCES

- Lomelino CL, McKenna R. Carbonic anhydrase II in complex with carboxylic acid-based inhibitors. *Acta Crystallographica Section F: Structural Biol Commun.* 2019;75(3):166-70.
- Tacharina MR, Ansori ANM, Plumeriastuti H, Kusnoto, Kurnijasanti R, Hestianah EP. Beneficial effect of grinting grass (*Cynodon dactylon*) on the streptozotocin induced diabetes mellitus in the mice. *Indian Vet J.* 2020; 97(4): 35-38.
- Filippini T, Malavolti M, Borrelli F, Izzo AA, Fairweather-Tait SJ, Horneber M, *et al.* Green tea (*Camellia sinensis*) for the prevention of cancer. *Cochrane Database Syst Rev.* 2020;3(3):CD005004.
- Prasanth MI, Sivamaruthi BS, Chaiyasut C, Tencomnao T. A review of the role of green tea (*Camellia sinensis*) in antiphotaging, stress resistance, neuroprotection, and autophagy. *Nutrients.* 2019;11(2):474.
- Vishnoi H, Bodla RB, Kant R, Bodla RB. Green Tea (*Camellia sinensis*) and its antioxidant property: A review. *Int J Pharm Sci Res.* 2018;9(5):1723-36.
- Kellogg JJ, Graf TN, Paine MF, McCune JS, Kvalheim OM, Oberlies NH, *et al.* Comparison of metabolomics approaches for evaluating the variability of complex botanical preparations: green tea (*Camellia sinensis*) as a case study. *J Nat Prod.* 2017;80(5):1457-66.
- Horita S, Nakamura M, Suzuki M, Satoh N, Suzuki A, Homma Y, *et al.* The role of renal proximal tubule transport in the regulation of blood pressure. *Kidney Res Clin Pract.* 2017;36(1):12.
- Luo Q, Zhang JR, Li HB, Wu DT, Geng F, Corke H, *et al.* Green extraction of antioxidant polyphenols from green tea (*Camellia sinensis*). *Antioxidants.* 2020;9(9):785.

9. Ansori ANM, Kharisma VD, Parikesit AA, Dian FA, Probojati RT, Rebezov M, et al. Bioactive compounds from mangosteen (*Garcinia mangostana* L.) as an antiviral agent via dual inhibitor mechanism against SARS-CoV-2: an in silico approach. *Pharmacogn J.* 2022;14(1).
10. Zhao T, Li C, Wang S, Song X. Green tea (*Camellia sinensis*): A review of its phytochemistry, pharmacology, and toxicology. *Molecules.* 2022;27(12):3909.
11. Aini NS, Kharisma VD, Widyananda MH, Murtadlo AAA, Probojati RT, Turista DDR, et al. In Silico Screening of Bioactive Compounds from *Garcinia mangostana* L. Against SARS-CoV-2 via Tetra Inhibitors. *Pharmacogn J.* 2022;14(5).
12. Rahmah, Salimo H, Wasita B, Pamungkasari EP, Cilmiaty R, Soetrisno. *Mesona palustris* BL: the potential antioxidant. *Bali Med J.* 2023;12(1):560-2.
13. Albassam AA, Markowitz JS. An appraisal of drug-drug interactions with green tea (*Camellia sinensis*). *Planta Medica.* 2017;234(6):496-508.
14. Topal F, Aksu K, Gulcin I, Tümer F, Goksu S. Inhibition profiles of some symmetric sulfamides derived from phenethylamines on human carbonic anhydrase I, and II isoenzymes. *Chem Biodiv.* 2021;18(10):e2100422.
15. Hayaza S, Istiqomah S, Kuncoroningrat Susilo RJ, Inayatillah B, Ansori ANM, Winarni D et al. Antidiabetic activity of ketapang (*Terminalia catappa* L.) leaves extract in streptozotocin-induced diabetic mice. *Indian Vet J.* 2019; 96(12): 11-13.
16. Husen SA, Winarni D, Salamun, Ansori ANM, Susilo RJK, Hayaza S. Hepatoprotective effect of gamma-mangostin for amelioration of impaired liver structure and function in streptozotocin-induced diabetic mice. *IOP Confer Ser: Earth Env Sci.* 2019; 217(1): 012031.
17. Réau M, Langenfeld F, Zagury JF, Lagarde N, Montes M. Decoys selection in benchmarking datasets: Overview and perspectives. *Front Pharmacol.* 2019;9(1).
18. Listiyani P, Kharisma VD, Ansori ANM, Widyananda MH, Probojati RT, Murtadlo AAA, et al. In silico phytochemical compounds screening of *Allium sativum* targeting the Mpro of SARS-CoV-2. *Pharmacogn J.* 2022;14(3).
19. Lemkul J. From Proteins to Perturbed Hamiltonians: A Suite of Tutorials for the GROMACS-2018 Molecular Simulation Package [Article v1.0]. *Living J Comp Mol Sci.* 2019;1(1):1-53.
20. Ojo OA, Ojo AB, Okolie C, Nwakama MAC, Iyobhebhe M, Ebuomwan IO, et al. Deciphering the interactions of bioactive compounds in selected traditional medicinal plants against alzheimer's diseases via pharmacophore modeling, auto-QSAR, and molecular docking approaches. *Molecules.* 2021;26(7).
21. Kharisma VD, Ansori ANM, Dian FA, Rizky WC, Dings TGA, Zainul R, et al. Molecular Docking and Dynamic Simulation Of Entry Inhibitor From *Tamarindus Indica* Bioactive Compounds Against Sars-Cov-2 Infection Via Viroinformatics Study. *Biochem Cell Arch.* 2021;21(2):3323-7.
22. Murtadlo AAA, Listiyani P, Utami SL, Wahyuningsih S, Turista DDR, Wiguna A, et al. Molecular Docking Study of *Nigella sativa* Bioactive Compound as E6 Inhibitor Against Human Papillomavirus (HPV) Infection. *SAINSTEK Int J Appl Sci Adv Technol Inform.* 2022;1(2):32-8.
23. Chen X, Li H, Tian L, Li Q, Luo J, Zhang Y. Analysis of the physicochemical properties of acaricides based on Lipinski's rule of five. *J Comp Biol.* 2020;27(9):1397-406.
24. Mawaddani N, Sutiyaniti E, Widyananda MH, Kharisma VD, Turista DDR, Tamam MB, et al. In Silico Study of Entry Inhibitor from *Moringa oleifera* Bioactive Compounds against SARS-CoV-2 Infection. *Pharmacogn J.* 2022;14(5).
25. Lin X, Li X, Lin X. A review on applications of computational methods in drug screening and design. *Molecules.* 2020;25(6):1-17.
26. Patel H, Kukol A. Integrating molecular modelling methods to advance influenza A virus drug discovery. *Drug Discovery Today.* 2021;26(2):503-10.
27. Islamiati Y, Suryani Y, Adawiyah A, Taufiqurrohman O, Kharisma VD, Purnamasari D, et al. The Potential of Antivirus Compounds in Gletang (*Tridax procumbens* Linn.) in Inhibiting 3CLpro Receptor of SARS-CoV-2 Virus by In Silico. *Pharmacogn J.* 2022;14(6).
28. Ivanović V, Rančić M, Arsić B, Pavlović A. Lipinski's rule of five, famous extensions and famous exceptions. *Popular Scientific Article.* 2020;3(1):171-7.
29. Dibha AF, Wahyuningsih S, Ansori ANM, Kharisma VD, Widyananda MH, Parikesit AA, et al. Utilization of secondary metabolites in algae *Kappaphycus alvarezii* as a breast cancer drug with a computational method. *Pharmacogn J.* 2022;14(3).
30. Naw SW, Probojati RT, Murtadlo AAA, Ullah ME. Computational Drug Design Study of *Curcuma longa* L. Compound as HPV-16 Antiviral Candidate Against Cervical Cancer. *SAINSTEK Int J Appl Sci Adv Technol Inform.* 2022;1(1):1-6.
31. Hemalatha G, Sivakumari K, Rajesh S. In silico molecular docking studies of muricin J, muricin K and muricin L compound from *A. muricata* againsts apoptotic proteins (caspase-3, caspase-9 and β -actin). *Innoriginal Originating Innov.* 2020;7(5):1-4.
32. Prahasanti C, Nugraha AP, Kharisma VD, Ansori ANM, Ridwan RD, Putri TPS, et al. A bioinformatic approach of hydroxyapatite and polymethylmethacrylate composite exploration as dental implant biomaterial. *J Pharm Pharmacogn Res.* 2021; 9(5): 746-754.
33. Pang KL, Mai CW, Chin KY. Molecular Mechanism of Tocotrienol-Mediated Anticancer Properties: A Systematic Review of the Involvement of Endoplasmic Reticulum Stress and Unfolded Protein Response. *Nutrients.* 2023;15(8):1854.
34. Balachandran A, Choi SB, Beata MM, Małgorzata J, Froemming GRA, Lavilla CA Jr, et al. Antioxidant, Wound Healing Potential and In Silico Assessment of Naringin, Eicosane and Octacosane. *Molecules.* 2023;28(3):1043.
35. Wai SN, How YH, Saleena LAK, Degraeve P, Oulalah N, Pui LP. Chitosan-Sodium Caseinate Composite Edible Film Incorporated with Probiotic *Limosilactobacillus fermentum*: Physical Properties, Viability, and Antibacterial Properties. *Foods.* 2022;11(22):3583.
36. Xiong G, Wu Z, Yi J, Fu L, Yang Z, Hsieh C, et al. ADMETlab 2.0: An integrated online platform for accurate and comprehensive predictions of ADMET properties. *Nucleic Acids Research.* 2021;49(W1):W5-14.
37. Wijaya RM, Hafidzhah MA, Kharisma VD, Ansori ANM, Parikesit AA. Covid-19 in silico drug with *Zingiber officinale* natural product compound library targeting the mpro protein. *Makara J Sci.* 2021; 25(3): 162-171.
38. Kharisma VD, Probojati RT, Murtadlo AAA, Ansori ANM, Antonius Y, Tamam MB. Revealing potency of bioactive compounds as inhibitor of dengue virus (DENV) NS2b/NS3 protease from sweet potato (*Ipomoea batatas* L.) leaves. *Indian J Forens Med Toxicol.* 2021; 15(1): 1627-1632.
39. Kharisma VD, Ansori ANM, Nugraha AP. Computational study of ginger (*Zingiber officinale*) as E6 inhibitor in human papillomavirus type 16 (HPV-16) infection. *Biochem Cell Arch.* 2020; 20: 3155-3159.
40. Tamam MB, Naw SW, Ullah ME, Probojati RT, Murtadlo AAA, Turista DDR. Virtual Screening of *Kaempferia galanga* L. Bioactive Compounds as HPV-16 Antiviral Mechanism Through E6 Inhibitor Activity. *SAINSTEK Int J Appl Sci Adv Technol Inform.* 2022;1(1):7-13.
41. Pinzi L, Rastelli G. Molecular docking: Shifting paradigms in drug discovery. *Int J Mol Sci.* 2019;20(18):4331.

42. Khairullah AR, Solikhah TI, Ansori ANM, Fadholly A, Ramandinianto SC, Ansharieta R, Widodo A, Rivu KHP, Putri N, Proboningrat A, Kusala MKJ, Rendragraha BW, Putra ARS, Anshori A. A review of an important medicinal plant: *Alpinia galanga* (L.) Willd. *Syst Rev Pharm.* 2020; 11(10): 387-395.
43. Ghorai S, Pulya S, Ghosh K, Panda P, Ghosh B, Gayen S. Structure-activity relationship of human carbonic anhydrase-II inhibitors: Detailed insight for future development as anti-glaucoma agents. *Bioorganic Chem.* 2020;95(1):103557.
44. Noor SI, Jamali S, Ames S, Langer S, Deitmer JW, Becker HM. A surface proton antenna in carbonic anhydrase II supports lactate transport in cancer cells. *Elife.* 2018;7(1):e35176.
45. Wahyuni DK, Ansori ANM, Vidiyanti F. GC-MS analysis of phytochemicals in methanolic extracts of leaf-derived callus of *Justicia gendarussa* Burm.f. *Biosci Res.* 2017; 14(3): 668-677.
46. Rahmah, Salimo H, Wasita B, Pamungkasari EP, Cilmiaty R, Soetrisno. *Mesona palustris* BL: the potential antioxidant. *Bali Med J.* 2023;12(1):560-2.
47. Agung IGAA, Wahjuni S, Wedagama DM, Weta IW, Lestari AAW. Nutraceuticals of nano-betel (*Piper betle* L.) leaves: prevent COVID-19 and oral cavity disease. *Bali Med J.* 2022;11(2):844-9.
48. Purnawati S, Wrsiati LP, Jaya Lesmana CB, Megantara S, Lesmana R. A study of molecular docking of L-tryptophan ligand as a compound in pineapples and bananas binding with the human serotonin transporter (SERT). *Bali Med J.* 2022;11(3):1243-9.
49. Listari KM, Az-Zahra T, Hasanah A, Agistasari Y. *Jatropha multifida* L stem sap gel versus Aloe vera gel to post-gingivectomy healing process. *Bali Med J.* 2023;12(1):432-6.
50. Nora H, Rajuddin, Hafizudin, Suhandi R, Indirayani I. Curcumin, a potential oral herbal male contraceptive: a review article. *Bali Med J.* 2022;12(1):82-6.
51. Rosita E, Prasetyo SA, Riwanto I, Atmodjo WL. The effect of Epigallocatechin-3-Gallate (EGCG) combined with low dose sorafenib in apoptosis and Platelet-Derived Growth Factor Receptor (PDGFR) expression in hepatocellular carcinoma rats. *Bali Med J.* 2022;11(1):216-22.
52. Sulistyowati E, Aziz MR. Systematic literature review: potential anti hyperglycemia *Imperata cylindrica*. *Bali Med J.* 2022;11(2):752-6.
53. Abbas N, Al-Shamary, Abbas S, Al-Mizraqchi. The Combination Effects of Honey and Nicotine on the Acid Production of Oral Mutans *Streptococci*. *J Med Chem Sci.* 2023;6(6):1410-8.
54. Abdullah SM, AL-Hamdani AAS, Ibrahim SM, Al-Zubaid LA, Rashid FA. An Evaluation of Activity of Prepared Zinc Nanoparticles with Extract Green Plant in Treatments of Diclofenac, Levofloxacin, and Tetracycline in Water. *J Med Chem Sci.* 2023;6(6):1323-35.
55. Yedelli K, Pathangi RK. Assessment of Anti-Diabetic and Antioxidant Activities of *Rourea Minor* Stems in Streptozotocin-Induced Diabetic Rats. *J Med Chem Sci.* 2023;6(6):1370-82.
56. Hamzah BF, Taha I, Najm ZM, Husseini MD, Noor SK, Al-Khafaji. Synthesis, Characterization, and Antibacterial Activity of Some New Oxazepine Derivatives. *J Med Chem Sci.* 2023;6(6):1239-45.
57. Qasim MA, Yaaqoob LA. Evaluation of Antibacterial Activity of Iron Oxide Nanoparticles Synthesis by Extracellular *Lactobacillus* against *Pseudomonas Aeruginosa*. *J Med Chem Sci.* 2023;6(5):1100-11.

GRAPHICAL ABSTRACT



ABOUT AUTHORS



Rahadian Zainul is a Professor in Physical Chemistry and researcher in CAMPBIOTICS, Universitas Negeri Padang, Indonesia. His research projects are related to virology, bioinformatics, advanced material and also in computational chemistry. He was published more than 71 papers in Scopus and WOS with more than 150 researchers in the world as collaborator.



Rismi Verawati is a Bachelor Student at Chemistry Department in Universitas Negeri Padang, Indonesia. Her research area of interest is Organic Chemistry and Pharmacology. She is also as assistant reseacher in CAMPBIOTICS, Universitas Negeri Padang, Indonesia since 2022 till now.

Cite this article: Zainul R, Verawati R, Suprijono A, Mandeli RS, Wulandari AP, Novaliendry D, et al. *In Silico* Study on the Potential of Guaiacol Extract from Green Tea (*Camellia sinensis*) as a Stimulant for Carbanic Anhydrase II in Renal Tubular Acidosis. *Pharmacogn J.* 2023;15(4): 494-499.